Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $279 | $242 | $417 | $872 |
| - Cash | $102 | $136 | $135 | $52 |
| + Debt | $12 | $9 | $11 | $12 |
| Enterprise Value | $189 | $116 | $293 | $832 |
| Revenue | $199 | $193 | $254 | $269 |
| % Growth | 3.2% | -24.3% | -5.3% | – |
| Gross Profit | $187 | $178 | $230 | $243 |
| % Margin | 94.3% | 92.3% | 90.5% | 90.5% |
| EBITDA | -$33 | -$11 | $9 | $45 |
| % Margin | -16.4% | -5.7% | 3.6% | 16.8% |
| Net Income | -$19 | $3 | $6 | $33 |
| % Margin | -9.5% | 1.3% | 2.5% | 12.3% |
| EPS Diluted | -0.32 | 0.044 | 0.11 | 0.58 |
| % Growth | -833.9% | -60.4% | -81% | – |
| Operating Cash Flow | -$16 | $13 | $32 | $64 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$16 | $12 | $31 | $64 |